Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

is trial. Efficacy evaluations will include the measure of target lesions (per RECIST), and the quantization of symptom relief. Further details of this trial can be found at http://www.clinicaltrials.gov.

The other five sites currently participating in this Phase II trial are: 1) the Hematology Oncology Services of Arkansas in Little Rock, Arkansas, 2) the Dana-Farber Cancer Institute in Boston, MA. 3) Mount Sinai in New York City, 4) Lahey Clinic in Burlington, MA. and 5) Scott & White Memorial Hospital in Temple TX.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Callisto earlier announced in June, 2006 interim data from a Phase I trial of Atiprimod in advanced cancer patients. The patients who were entered into this trial had growing tumors and symptoms that were no longer controlled by the standard therapies utilized. During treatment, three of the five advanced carcinoid patients had measurable tumor regressions and loss of many of the debilitating symptoms of this disease.

About Carcinoid Cancer

Carcinoid tumors, or carcinoids, originate in hormone-producing cells of the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. Approximately 7,000 cases of carcinoid cancer are diag
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Gibraltar Associates, a leading public ... domestic communications and issues management, today announced ... PositiveID Corporation (Nasdaq: PSID ) to ... of record. Gibraltar Associates will conduct media ... the Company on its public relations programs. ...
(Date:12/14/2009)... -- Cardium Therapeutics (NYSE Amex: CXM ) ... GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers," ... Industry Conference held December 10-13, 2009 in St. ... attended by top industry leaders and renowned researchers ... Dr. Barbara K. Sosnowski, Cardium,s Vice President of ...
(Date:12/14/2009)... At GeoInvesting.com, we have been tracking Tianyin ... now. Our largest hang up had been with the ... June 2010 net income guidance of $11.3 million represents ... income of $7.9 million, the increase in shares poses ... which depends upon the share price and the Treasury ...
Breaking Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 11099 1UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 11099 2Princeton scientists find way to catalog all that goes wrong in a cancer cell 11094 1Princeton scientists find way to catalog all that goes wrong in a cancer cell 11094 2Canna can 3A Ornamental eliminates pollutants from stormwater runoff 11093 1Canna can 3A Ornamental eliminates pollutants from stormwater runoff 11093 2
(Date:12/14/2009)... 29,000 future cancers could be linked to scans performed in ... performed CT scans are exposing patients to far more radiation ... of thousands of cancers a year, two new studies claim. ... issue of the Archives of Internal Medicine , the ... F. Redberg, are calling on clinicians to limit radiation exposure ...
(Date:12/14/2009)... are linked to an increased risk of certain cancers. ... synthetic insulin preparation marketed under the trade name Lantus), ... cancers than other insulins or oral glucose lowering medications. ... important factors such as obesity that may have driven ... large randomized trial designed to examine another aspect of ...
(Date:12/14/2009)... meth and smoking, but concerns about prescription abuse, ... Fewer teenagers are using methamphetamine, but reductions in ... drugs remains high, U.S. health officials report. , ... as the hallucinogenic salvia leaf and the prescription ... attention-deficit hyperactivity disorder (ADHD), appear to be gaining ...
(Date:12/14/2009)... Urges Congress to Ensure Health Workforce Recommendations ... Congressional leaders must ensure that ... body with sufficient authority to ensure implementation ... policy, according to Dr. Steven A Wartman, ... Academic Health Centers (AAHC). "With each ...
(Date:12/14/2009)... Dec. 14 Following is a statement ... Kids: ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ,, The ... the National Institute of Drug Abuse shows that ... reducing youth smoking, but declines have slowed significantly ... decade. In especially troubling news, the survey ...
Breaking Medicine News(10 mins):Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 3Health News:Marijuana Use No Longer Dropping Among U.S. Teens 4Health News:Health Reform Needs Enforceable National Workforce Strategy 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 3Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 4Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 5
... known as scleroderma, is characterized by the formation of ... as the skin. Beyond its disfiguring symptoms, SSc is ... Pulmonary fibrosis strikes at least one-third of SSc sufferers, ... treating SSc remains challenging, despite recent clinical trials, due ...
... Teams Choose Best Plans for Their Brands, ... Qforma, an advanced analytics,company, today announced the ... This innovative new tool was developed to ... and,pull-through strategies. iQMCO(TM) utilizes advanced modeling techniques ...
... In a two-minute, forty-one second,video released today by ... in the nation executive weight loss,consulting service for ... Leventhal,Weight Loss Incorporated team physician both praise the ... on the company,s website:, http://www.attorneyweightloss.com ., "This ...
... Microflex Corporation (Reno, NV),a subsidiary of BarrierSafe ... new website designed by Project6, a San Francisco,Bay ... offers a fresh interface, significantly improved,navigation, and new ... right glove for their application., "It,s a ...
... to,the State of Iowa,s new smoke-free law, the American ... Tobacco-Free" conference on April,29th in Coralville, Iowa to assist ... will offer information on the new law,and feature speakers ... businesses that have questions about the law and the ...
... ROCKVILLE, Md., April 14 The United States,Pharmacopeial ... the Food,and Drug Administration (FDA) to develop more ... widely used blood-thinning,drug heparin. This contamination is suspected ... has resulted in over 60 deaths. The,suspected contaminant, ...
Other Medicine News:Health News:Study sheds light on deadly lung disease 2Health News:Study sheds light on deadly lung disease 3Health News:Qforma Unveils Managed Care Optimization Solution for Pharma Marketing Executives 2Health News:Client and Physician Praise Benefits of Leventhal Weight Loss Incorporated 2Health News:Microflex Corporation Launches New Website 2Health News:U.S. Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: